Cecelia Koetting, OD: AbbVie/Allergan: Consulting Fees (); Alcon: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Bausch + Lomb: Consulting Fees (), Independent Contractor (including contracted research) (), Speaker's Bureau (honoraria or other compensation) (); Blephex: Consulting Fees (); bruder: Consulting Fees (); Dompe: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Glaukos: Consulting Fees (); harrow: Speaker's Bureau (honoraria or other compensation) (); Movu: Advisory Committee/Board Member (), Consulting Fees (); Myze: Consulting Fees (); nulids: Consulting Fees (); Topcon: Consulting Fees (); viatris: Speaker's Bureau (honoraria or other compensation) ()
Explore the evolving role of compounded medications in eyecare, from treating ocular surface disease to managing corneal ulcers, endophthalmitis or even myopia. This lecture covers clinical indications, regulatory considerations, formulation tips, and patient counseling strategies to help you integrate customized therapies into your practice confidently and compliantly.
Learning Objectives:
Upon conclusion of this activity, attendees will be able to:
Understand the clinical indications for compounded ophthalmic medications.
Discuss current applications of compounded therapies in managing ocular surface and anterior segment disease.
Discuss potential future uses and regulatory considerations of compounded medications in eyecare.
